<DOC>
	<DOCNO>NCT00003128</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether ifosfamide alone effective ifosfamide plus paclitaxel treating patient cancer uterus . PURPOSE : Randomized phase III trial compare effectiveness ifosfamide without paclitaxel treat patient advance , refractory , recurrent cancer uterus .</brief_summary>
	<brief_title>Ifosfamide With Without Paclitaxel Treating Patients With Advanced , Refractory , Recurrent Cancer Uterus</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether addition paclitaxel ifosfamide improve length survival , progression free interval response rate compare ifosfamide alone patient advance , refractory recurrent carcinosarcoma ( mixed mesodermal tumor ) uterus . - Determine toxicity ifosfamide paclitaxel patient . OUTLINE : This randomize study . Patients stratify accord GOG performance status ( GOG 0-1 v GOG 2-3 ) randomize one two treatment arm . - Arm I : Patients receive ifosfamide IV daily 3 day every 21 day . - Arm II : Patients receive paclitaxel IV day 1 ifosfamide IV day 1-3 every 21 day . Filgrastim ( G-CSF ) give subcutaneously begin day 4 granulocyte count great 2,000/mm3 . Paclitaxel therapy may precede give concurrently ifosfamide . Treatment arm continue maximum 8 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month additional 3 year , annually thereafter . PROJECTED ACCRUAL : A total 166 patient ( 83 per arm ) accrue study within approximately 5.5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV , refractory , recurrent heterologous homologous carcinosarcoma ( mixed mesodermal tumor ) uterus Must amenable curativeintent therapy Must measurable disease consist abdominal , pelvic , chest mass define least 2 dimension palpation , xray , MRI , compute tomography ultrasound If measure MRI , compute tomography ultrasound , lesion must minimal tumor measurement 1 cm PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Albumin least 3 g/dL Bilirubin great 1.5 time normal SGOT great 3 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No history congestive heart failure No unstable angina No myocardial infarction within past 6 month Other : No septicemia No severe infection No acute hepatitis No gastrointestinal bleeding At least 5 year since invasive malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy carcinosarcoma uterus Endocrine therapy : Not specify Radiotherapy : At least 6 week since radiotherapy current malignancy At least 3 month since radiotherapy deliver site measurable disease Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
</DOC>